FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381144796> ?p ?o ?g. }

• W4381144796 abstract "<h3>Objective</h3> To assess the outcomes of newborns responsive with low dose diazoxide (≤ 5 mg/kg/day in 3 divided doses) in biochemically confirmed HI. <h3>Methods</h3> A retrospective analysis of 19 patients successfully treated with low-dose diazoxide at Royal London Children’s Hospital from May 2020 to January 2023 was carried out. Treatment success was defined as normal glycaemic control on diazoxide after appropriate fasting for age (generally 6–8 hours) when discharged from NICU. We measured four outcomes of these newborns: (1) discharge dose of diazoxide; (2) age when diazoxide was stopped after a successful age-appropriate fast test; (3) neurodevelopmental outcomes; and (4) side effects of medications. Biochemically confirmed HI patients were identified using the hospital’s electronic patient database. Patient records were extracted and analysed. Patient characteristics were explored to identify any associations with their outcomes. These included demographic data as well as gestational age, birthweight, perinatal history and family history. Neurodevelopment was tracked through patient documentation during follow-ups. <h3>Results</h3> Patients were divided into two groups based on their gestational age: (1) small for gestational age (SGA); and (2) Non-SGA (appropriate for gestational age (AGA) and large for gestational age (LGA)). Subgroup analysis of the patient characteristics is summarised in table 1. All babies had total fluid volume adjusted to 130mls/kg/day when initiating diazoxide and diuretics and had normal echocardiogram on discharge. During follow-up, 6 (31.6%) patients required an increase in dosage of diazoxide by 1.2–3mg/day, with the total daily dosage still remaining <5 mg/kg/day given the patients’ weight gain. 3 (15.8%) patients had episodes of minimal fluid retention noted on follow up and all were adjusted with an increase in diuretics dose. 1 (5.26%) patient had a genetic confirmation of HNF4A. The patients were an average of 4.16 (2–10) months of age when they stopped diazoxide. No neurodevelopmental concerns were identified and all milestones were appropriate on follow-up so far. <h3>Conclusion</h3> This retrospective analysis shows that starting on low-dose diazoxide may be a possible initial treatment for babies likely to have transient hyperinsulinism and persistent hypoglycaemia beyond a few weeks in the neonatal period. The lower doses of diazoxide could avoid potential side effects like pulmonary hypertension and reduce the number of days patients are on medications. More importantly, regular blood glucose monitoring, as well as neurodevelopment follow-up, would be advisable to plan the treatment of these patients." @default.
• W4381144796 created "2023-06-19" @default.
• W4381144796 creator A5005866115 @default.
• W4381144796 creator A5075915335 @default.
• W4381144796 date "2023-06-19" @default.
• W4381144796 modified "2023-09-27" @default.
• W4381144796 title "581 Outcomes of children with hyperinsulinaemic hypoglycaemia responsive to low-dose diazoxide" @default.
• W4381144796 doi "https://doi.org/10.1136/archdischild-2023-rcpch.407" @default.
• W4381144796 hasPublicationYear "2023" @default.
• W4381144796 type Work @default.
• W4381144796 citedByCount "0" @default.
• W4381144796 crossrefType "proceedings-article" @default.
• W4381144796 hasAuthorship W4381144796A5005866115 @default.
• W4381144796 hasAuthorship W4381144796A5075915335 @default.
• W4381144796 hasConcept C126322002 @default.
• W4381144796 hasConcept C131872663 @default.
• W4381144796 hasConcept C167135981 @default.
• W4381144796 hasConcept C187212893 @default.
• W4381144796 hasConcept C195910791 @default.
• W4381144796 hasConcept C2778376644 @default.
• W4381144796 hasConcept C2779234561 @default.
• W4381144796 hasConcept C2779306644 @default.
• W4381144796 hasConcept C2779872217 @default.
• W4381144796 hasConcept C2780938740 @default.
• W4381144796 hasConcept C46973012 @default.
• W4381144796 hasConcept C54355233 @default.
• W4381144796 hasConcept C71924100 @default.
• W4381144796 hasConcept C86803240 @default.
• W4381144796 hasConceptScore W4381144796C126322002 @default.
• W4381144796 hasConceptScore W4381144796C131872663 @default.
• W4381144796 hasConceptScore W4381144796C167135981 @default.
• W4381144796 hasConceptScore W4381144796C187212893 @default.
• W4381144796 hasConceptScore W4381144796C195910791 @default.
• W4381144796 hasConceptScore W4381144796C2778376644 @default.
• W4381144796 hasConceptScore W4381144796C2779234561 @default.
• W4381144796 hasConceptScore W4381144796C2779306644 @default.
• W4381144796 hasConceptScore W4381144796C2779872217 @default.
• W4381144796 hasConceptScore W4381144796C2780938740 @default.
• W4381144796 hasConceptScore W4381144796C46973012 @default.
• W4381144796 hasConceptScore W4381144796C54355233 @default.
• W4381144796 hasConceptScore W4381144796C71924100 @default.
• W4381144796 hasConceptScore W4381144796C86803240 @default.
• W4381144796 hasLocation W43811447961 @default.
• W4381144796 hasOpenAccess W4381144796 @default.
• W4381144796 hasPrimaryLocation W43811447961 @default.
• W4381144796 hasRelatedWork W1994424147 @default.
• W4381144796 hasRelatedWork W1999907682 @default.
• W4381144796 hasRelatedWork W2018250552 @default.
• W4381144796 hasRelatedWork W2029447643 @default.
• W4381144796 hasRelatedWork W2059009258 @default.
• W4381144796 hasRelatedWork W2099616324 @default.
• W4381144796 hasRelatedWork W2765222358 @default.
• W4381144796 hasRelatedWork W2906386199 @default.
• W4381144796 hasRelatedWork W2914985152 @default.
• W4381144796 hasRelatedWork W2990951702 @default.
• W4381144796 isParatext "false" @default.
• W4381144796 isRetracted "false" @default.
• W4381144796 workType "article" @default.